Delisting riskPopularity #4,472
Aspire Biopharma (ASBP)
Developer of sublingual drug and supplement formulations, including aspirin candidates and Buzz Bomb.
$8.20
After hours−0.01 (−0.17%)
At close$8.21(−5.80%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 0.06% | 845 shares | |
|---|---|---|---|
| 2 holders · as of Mar 31, 2026 | |||
| Insiders | 0.00% | 17 shares | |
| 1 holder · as of Jun 10, 2025 | |||
| Other | 99.94% | 1.40M shares | |
| remainder | |||
1.40M company shares as of Sep 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (1.40M in the company's Sep 22, 2026 report, 115.4K elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
13F, as of Mar 31, 2026
2 holders · 25.3K shares
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Crossingbridge Advisors, LLC | 24.3K | 1.74% | May 14, 2026 | |
| Hallmark Capital Management Inc | 1.0K | 0.07% | May 6, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Gary Shirinyan | 7.70% | 13G | Aug 10, 2026 | |
| Highbridge Capital Management, LLC | 5.20% | 13G | May 15, 2026 | |
| Rubenbauer Alois Ryan III | 5.00% | 13G | Jul 2, 2026 |
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.